High levels of PD-L1, detected by immunohistochemistry, are associated with the response to immunotherapy in melanoma, non-small cell lung carcinoma (NSCLC), renal cell carcinoma, colorectal carcinoma, and castration-resistant prostate cancer [39,40,41,42]. This evidence concerns the gene CD274 and renal cell carcinoma.